Abstract
Catalytic activity of certain antibodies was proposed by Linus Pauling for the very first time more than six decades ago. Since then few examples of catalytic antibodies (abzymes) were found in human organism. From late 80s many synthetic abzymes were obtained after immunization by Transition State Analogs (TSA). Another approach is based on functional mimicry of antibody to an active site of an enzyme. Detection of an abzymatic activity requires special immunoassays. This unique strategy can be employed for new methods of drug synthesis, as well as for in vivo therapies. Catalytic antibodies seem to be a promising tool for therapeutic purposes, because of their specifity and stereoselectivity.
Keywords: Catalytic antibodies, abzymes, transition state analogs, antibody-directed abzyme prodrug therapy
Current Medicinal Chemistry
Title: Catalytic Activity of Certain Antibodies as a Potential Tool for Drug Synthesis and for Directed Prodrug Therapies
Volume: 15 Issue: 16
Author(s): T. Wojcik and K. Kiec-Kononowicz
Affiliation:
Keywords: Catalytic antibodies, abzymes, transition state analogs, antibody-directed abzyme prodrug therapy
Abstract: Catalytic activity of certain antibodies was proposed by Linus Pauling for the very first time more than six decades ago. Since then few examples of catalytic antibodies (abzymes) were found in human organism. From late 80s many synthetic abzymes were obtained after immunization by Transition State Analogs (TSA). Another approach is based on functional mimicry of antibody to an active site of an enzyme. Detection of an abzymatic activity requires special immunoassays. This unique strategy can be employed for new methods of drug synthesis, as well as for in vivo therapies. Catalytic antibodies seem to be a promising tool for therapeutic purposes, because of their specifity and stereoselectivity.
Export Options
About this article
Cite this article as:
Wojcik T. and Kiec-Kononowicz K., Catalytic Activity of Certain Antibodies as a Potential Tool for Drug Synthesis and for Directed Prodrug Therapies, Current Medicinal Chemistry 2008; 15 (16) . https://dx.doi.org/10.2174/092986708784911533
DOI https://dx.doi.org/10.2174/092986708784911533 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Induction of Cytoprotective Genes Through Nrf2 / Antioxidant Response Element Pathway: A New Therapeutic Approach for the Treatment of Inflammatory Diseases
Current Pharmaceutical Design Molecular Cytogenetics of Autism
Current Genomics Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets 2 Receptor Specific Ligand Conjugated Nanocarriers: An Effective Strategy for Targeted Therapy of Tuberculosis
Current Drug Delivery The Contribution of Extracellular Nef to HIV-Induced Pathogenesis
Current Drug Targets Mechanisms of Prion Protein Aggregation
Protein & Peptide Letters Can Dietary Antioxidants Reduce the Incidence of Brain Tumors?
Current Drug Metabolism Xanthone Derivatives: New Insights in Biological Activities
Current Medicinal Chemistry A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry Current Experimental Therapy for Alzheimers Disease
Current Neuropharmacology Current Evidence and Potential Mechanisms of Therapeutic Action of PEDF in Cervical Cancer Treatment
Current Molecular Medicine Unraveling Potential Candidate Targets Associated with Expression of p16<sup>INK4a</sup> or p16 Truncated Fragment by Comparative Proteomics Analysis
Current Proteomics Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry mTOR Targeted Cancer Chemoprevention by Flavonoids
Current Medicinal Chemistry Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Nasal Delivery of Antioxidants by Cholesterol-incorporated Liposomes Extends the Neuroprotective Time Window in Cerebral Ischemia
Current Pharmaceutical Design The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Current Enzyme Inhibition